CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9MG)

What Is the CJC-1295 & Ipamorelin & GHRP-2 Blend and Why Buy It for Research?

Buy CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland for research into growth hormone axis signaling, synergistic GH release, and metabolic regulation. Specifically, this 9mg research formulation combines three complementary growth hormone secretagogues in a single pre-mixed lyophilized vial: CJC-1295 (Mod GRF 1-29, 3mg), Ipamorelin (3mg), and GHRP-2 (3mg). This blend pairs a growth hormone-releasing hormone (GHRH) analog with two mechanistically distinct ghrelin receptor agonists to probe convergent pathways in the GH-IGF-1 axis.

CJC-1295 (without DAC, also known as Modified GRF 1-29) is a synthetic 29-amino acid peptide analog of GHRH that activates the GHRH receptor on anterior pituitary somatotrophs, driving cAMP/PKA-mediated GH synthesis and secretion. Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that engages the GHS-R1a receptor through Gq/11-coupled signaling, mobilizing intracellular calcium to trigger GH granule release. GHRP-2 (Pralmorelin) is a synthetic hexapeptide that also activates GHS-R1a but engages a broader signaling response, including hypothalamic circuits that suppress somatostatin and stimulate endogenous GHRH secretion. Furthermore, when combined, these three peptides produce synergistic GH release through convergent but mechanistically independent pathways. Moreover, Core Peptides supplies this blend as a lyophilized powder in a 9mg format exclusively for laboratory use. Therefore, researchers seeking to source this combination for their work will find it readily available when they buy CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland.

CJC-1295 & Ipamorelin & GHRP-2 Blend Research Overview: Buy CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland for GH Axis Studies

Centrally, research into the CJC-1295, Ipamorelin, and GHRP-2 blend has focused on the complementary and synergistic mechanisms of its three components. The foundational observation that GHRH + GHRP produces synergistic GH release was established by Bowers et al. in human subjects, demonstrating that co-administration of GHRH and GHRP produced GH peaks significantly higher than either peptide alone.

CJC-1295 (Mod GRF 1-29) functions as a GHRH analog that binds to the GHRH receptor (GHRH-R), a G-protein coupled receptor (GPCR) on pituitary somatotrophs. Importantly, the peptide incorporates four strategic amino acid substitutions at positions 2 (Ala to D-Ala), 8 (Asn to Gln), 15 (Gly to Ala), and 27 (Met to Leu), which confer resistance to DPP-IV cleavage and other degradation pathways, extending the biological half-life to approximately 30 minutes. As a result, this binding activates a downstream signaling cascade that results in GH synthesis and release.

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Specifically, it mimics ghrelin and binds to the ghrelin receptor (GHS-R1a) in the pituitary, thereby selectively stimulating the release of GH. Unlike other GH releasing peptides, ipamorelin only stimulates GH release in a manner very similar to that of growth hormone releasing hormone, with negligible cortisol or prolactin elevation.

GHRP-2 (Pralmorelin, KP-102) is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂. In addition to its direct pituitary effects, it acts indirectly on the hypothalamus, stimulating endogenous GHRH release from arcuate nucleus neurons and functionally suppressing somatostatin release from periventricular neurons. Consequently, this dual hypothalamic action creates a permissive environment for maximal GH pulse amplitude.

When combined, CJC-1295 sustains physiologic pulsatile GH secretion while Ipamorelin provides selective GH release and GHRP-2 amplifies output through hypothalamic effects and suppression of somatostatin. Therefore, the triple combination amplifies GH output through convergent but mechanistically independent pathways. Accordingly, researchers who buy CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland from Core Peptides can support their investigations into GH axis signaling, synergistic peptide interactions, and metabolic regulation.

How Does the CJC-1295 & Ipamorelin & GHRP-2 Blend Work in Research?

Mechanistically, the CJC-1295, Ipamorelin, and GHRP-2 blend operates through three complementary signaling pathways that converge on GH release from pituitary somatotrophs.

GHRH Receptor Pathway (CJC-1295)

CJC-1295 activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, driving cAMP/PKA-mediated GH synthesis and secretion. It functions as a stable and active hGRF1-29 analog with a half-life of approximately 30 minutes. As a result, this binding initiates a downstream signaling cascade that results in GH synthesis and release, with CJC-1295 showing a 4-fold increase in GH area under the curve over a 2-hour period compared with hGRF1-29.

GHS-R1a Pathway (Ipamorelin)

Ipamorelin binds GHS-R1a and activates Gq/11-coupled PLC signaling, generating IP3 and DAG. Consequently, the resulting intracellular calcium mobilization triggers rapid exocytosis of pre-formed GH vesicles. Notably, Ipamorelin’s key distinguishing feature is its failure to significantly stimulate ACTH or cortisol release at GH-effective doses, suggesting preferential activation of specific downstream signaling branches.

Broad Ghrelin Pathway (GHRP-2)

GHRP-2 also activates GHS-R1a but engages a broader signaling response. Beyond somatotroph GH release, GHRP-2 activates hypothalamic circuits that suppress somatostatin release and stimulate endogenous GHRH secretion, creating a feed-forward loop. In addition, this broader activation profile may contribute to metabolic effects beyond isolated GH release.

Synergistic Effects

The triple combination produces synergistic (not merely additive) GH release. Specifically, CJC-1295 sustains physiologic pulsatile GH secretion while Ipamorelin provides selective GH release and GHRP-2 amplifies output through hypothalamic effects and suppression of somatostatin. Moreover, combining two GHS-R1a agonists (Ipamorelin and GHRP-2) with a GHRH analog (CJC-1295) produces more complete receptor activation through potential differences in receptor binding kinetics, biased agonism profiles, and secondary target engagement.

Why Is the CJC-1295 & Ipamorelin & GHRP-2 Blend Studied in Switzerland?

Primarily, researchers study this blend because it represents a well-characterized triple combination of complementary GH secretagogues that enables investigation of synergistic GH release, metabolic regulation, and receptor pharmacology. In fact, this pre-mixed blend offers a practical way to study convergent GH axis signaling without the need to source and reconstitute each compound separately.

Research has demonstrated the blend’s relevance across multiple domains. For instance, GH pulse amplitude is a key determinant of recovery-relevant downstream effects including IGF-1 elevation, protein synthesis stimulation, lipolysis, and collagen synthesis. Furthermore, research in GH-deficient models demonstrates that pulsatile GH administration is more effective than continuous infusion for promoting lean body mass and reducing adiposity, supporting the value of high-amplitude pulse protocols. Additionally, Ipamorelin’s selective GH release profile with minimal cortisol elevation makes it valuable for studies requiring isolated GH effects. Likewise, GHRP-2’s broader hypothalamic effects provide additional mechanisms for amplifying GH output. Ultimately, researchers who buy CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland gain access to a comprehensive research tool for investigating GH axis signaling, metabolic regulation, and receptor pharmacology.

CJC-1295 & Ipamorelin & GHRP-2 Blend Research Areas in Laboratory Studies

Research Area	Focus	Key Components
GH Axis Signaling	Triple-pathway activation, GHRH/GHS receptor crosstalk, pulsatile secretion	All three (complementary pathways)
Metabolic Regulation	IGF-1 elevation, lipolysis, protein synthesis, metabolic homeostasis	All three (GH-dependent effects)
Receptor Pharmacology	GHRH-R, GHS-R1a binding, biased agonism, receptor binding kinetics	All three (distinct targets)
Hypothalamic-Pituitary Axis	Somatostatin suppression, endogenous GHRH release, feed-forward amplification	GHRP-2
Selective GH Release	GH-specific effects, minimal cortisol/prolactin spillover	Ipamorelin
Pulsatile GH Secretion	Physiologic GH patterning, amplitude modulation, pulse dynamics	CJC-1295

CJC-1295 & Ipamorelin & GHRP-2 Blend Compared With Related Research Formulations

Formulation	Components	Research Focus	Key Difference
CJC-1295 + Ipamorelin + GHRP-2 Blend	CJC-1295 + Ipamorelin + GHRP-2 (1:1:1)	Triple-pathway GH axis, synergistic release, receptor pharmacology	Most comprehensive GH amplification; dual GHS-R1a agonism
CJC-1295 + Ipamorelin Blend	CJC-1295 + Ipamorelin	GH release, metabolic regulation	Two-peptide blend; selective GH release, minimal cortisol
CJC-1295 + Hexarelin Blend	CJC-1295 + Hexarelin	GH axis, cardioprotection	Two-peptide blend; Hexarelin adds CD36 cardioprotection
CJC-1295 with DAC	CJC-1295 with Drug Affinity Complex	Sustained GH elevation, growth and metabolism	Single peptide; extended half-life (6-8 days)

Comparatively, the CJC-1295, Ipamorelin, and GHRP-2 blend differs from other GHRH/GHS combinations in its triple-pathway approach. On the one hand, the CJC-1295 and Ipamorelin blend provides selective GH release with minimal cortisol elevation. On the other hand, adding GHRP-2 introduces broader hypothalamic effects—including somatostatin suppression and endogenous GHRH stimulation—that further amplify GH output. In contrast, the CJC-1295 and Hexarelin blend adds CD36-mediated cardioprotection, while CJC-1295 with DAC provides sustained elevation rather than pulsatile release.

Research Applications for the CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland

Scientists have investigated this triple-peptide blend across several research domains:

• GH Axis Signaling Research: Researchers use this blend to study triple-pathway GH activation, GHRH/GHS receptor crosstalk, and pulsatile GH secretion dynamics.
• Metabolic Regulation Studies: The blend is employed to investigate IGF-1 elevation, lipolysis, protein synthesis, and metabolic homeostasis pathways.
• Receptor Pharmacology: The blend serves as a tool for studying GHRH-R, GHS-R1a binding, biased agonism, and receptor binding kinetics.
• Hypothalamic-Pituitary Axis Research: GHRP-2’s hypothalamic effects—somatostatin suppression and endogenous GHRH stimulation—are studied in neuroendocrine models.
• Selective GH Release Studies: Ipamorelin’s selective GH profile with minimal cortisol elevation is investigated in endocrine research.
• Pulsatile GH Secretion: CJC-1295’s pulsatile GH patterning is studied in models of physiologic GH secretion.

Evidently, researchers who buy CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland gain a valuable addition to any laboratory toolkit focused on GH axis signaling, metabolic research, and receptor pharmacology.

CJC-1295 & Ipamorelin & GHRP-2 Blend Product Specifications

Specification	Details
Product Name	CJC-1295 & Ipamorelin & GHRP-2 Blend
Alternative Names	Mod GRF 1-29 + Ipamorelin + GHRP-2, Triple GHRH/GHS blend, 3mg/3mg/3mg blend
Total Content	9mg
Composition	CJC-1295 (Mod GRF 1-29) 3mg + Ipamorelin 3mg + GHRP-2 3mg (1:1:1 ratio)
Form	Lyophilized powder
Purity	Not verified (≥98-99% HPLC purity reported by some suppliers)
CJC-1295 Sequence	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ (29 amino acids)
CJC-1295 Molecular Weight	Approximately 3,367.9 Da
CJC-1295 Molecular Formula	C₁₅₂H₂₅₂N₄₄O₄₂
Ipamorelin Sequence	Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (5 amino acids)
Ipamorelin Molecular Weight	711.85 Da
Ipamorelin Molecular Formula	C₃₈H₄₉N₉O₅
GHRP-2 Sequence	D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂ (6 amino acids)
GHRP-2 Molecular Weight	817.9 Da
GHRP-2 Molecular Formula	C₄₅H₅₅N₉O₆
Research Category	Growth Hormone Peptides / Muscle & Performance
Research Use	Laboratory research use only
CoA	Available upon request (not verified)
Storage	Lyophilized powder should be stored desiccated at -20°C or below, protected from light
Solubility	Soluble in water and bacteriostatic water; reconstitute slowly

How to Evaluate CJC-1295 & Ipamorelin & GHRP-2 Blend Quality for Research

When sourcing this triple-peptide blend for laboratory research, researchers should consider several quality indicators:

• Identity Confirmation: Analytical techniques such as mass spectrometry should confirm the identity and molecular weight of each component peptide.
• Purity Assessment: High-performance liquid chromatography (HPLC) should verify purity of each peptide, with ≥98% considered standard for research-grade material.
• Batch Traceability: Lot numbers and batch information enable researchers to track specific production runs.
• Certificate of Analysis: A CoA should accompany the product, detailing analytical testing results for each component.
• Labeling Accuracy: Proper labeling should clearly indicate the product name, composition (3mg CJC-1295 + 3mg Ipamorelin + 3mg GHRP-2), total content, and storage recommendations.
• Storage Conditions: Appropriate storage at -20°C or below in desiccated, dark conditions helps maintain peptide stability.

Understanding the Certificate of Analysis

Typically, a Certificate of Analysis (CoA) accompanies research peptide blends and provides information about the specific batch’s analytical testing. For example, a CoA may include product identity confirmation for each component, purity percentages as determined by HPLC, batch or lot number for traceability, analytical methods used (e.g., mass spectrometry, HPLC), and a physical description of the product.

Nevertheless, it is important to note that a CoA does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. Instead, it serves as a quality control document that helps researchers verify the identity and purity of the peptides they are using in their laboratory investigations.

Storage and Stability of the CJC-1295 & Ipamorelin & GHRP-2 Blend

Core Peptides supplies this blend as a lyophilized (freeze-dried) powder. To maintain stability and integrity:

• Store the lyophilized powder desiccated at -20°C or below for long-term storage
• Store at 4°C for short-term storage if frequent access is required
• Avoid repeated freeze-thaw cycles
• Reconstitute only immediately before use with appropriate sterile solvents (e.g., bacteriostatic water or sterile water)
• Inject solvent slowly against the inner wall of the vial rather than directly onto the powder; do not shake
• Gently roll the vial in a circular motion to dissolve
• Once reconstituted, refrigerate at 2°C to 8°C and utilize promptly
• Protect from light and moisture

Frequently Asked Questions About Buying the CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland

What is the CJC-1295 & Ipamorelin & GHRP-2 Blend?

Specifically, this 9mg blend combines CJC-1295 (Mod GRF 1-29, 3mg), Ipamorelin (3mg), and GHRP-2 (3mg) in a 1:1:1 ratio. It pairs a GHRH analog with two mechanistically distinct GHS-R1a agonists for triple-pathway GH release research.

What is the blend researched for?

Primarily, researchers study this blend for its triple-pathway synergistic GH release, metabolic regulation, and receptor pharmacology. It is most often discussed for GH axis signaling, receptor binding kinetics, and metabolic studies.

How does the blend work?

Mechanistically, CJC-1295 activates the GHRH receptor on pituitary somatotrophs, driving GH synthesis; Ipamorelin engages GHS-R1a, triggering selective GH release; and GHRP-2 amplifies output through hypothalamic effects and somatostatin suppression. Consequently, the combination produces synergistic GH output through convergent but mechanistically independent pathways.

What is the composition of the blend?

The blend contains CJC-1295 (Mod GRF 1-29) 3mg, Ipamorelin 3mg, and GHRP-2 3mg for a total of 9mg.

What is the amino acid sequence of CJC-1295?

CJC-1295 is a 29-amino acid peptide: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Notably, it selectively stimulates GH release with negligible cortisol or prolactin elevation.

What is GHRP-2?

GHRP-2 (Pralmorelin, KP-102) is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂. It activates GHS-R1a and engages broader hypothalamic signaling.

How does GHRP-2 differ from Ipamorelin?

Ipamorelin produces highly selective GH release with negligible cortisol or prolactin elevation, whereas GHRP-2 generates robust GH output alongside measurable increases in ACTH, cortisol, and prolactin, and activates hypothalamic circuits that suppress somatostatin.

What evidence exists for the blend?

The synergistic effect of combining GHRH analogs with GHSs is well-established in the literature. However, to date, there appear to be no published laboratory experiments evaluating the specific triple combination of CJC-1295, Ipamorelin, and GHRP-2. Each peptide has been studied individually for its respective mechanisms.

Is the blend approved as a medicine?

No. Regulatory authorities have not approved the blend as a medicine, pharmaceutical, or therapeutic agent. It is a research tool for laboratory use only.

Is the blend intended for human use?

No. The blend is intended for laboratory research use only and is not for human consumption, injection, or therapeutic application.

Where can I buy the CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland?

You can buy the CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland from Core Peptides, a trusted research peptide supplier serving the Swiss scientific community.

How should researchers evaluate the quality of this blend?

Researchers should look for identity confirmation via mass spectrometry for each component, purity data from HPLC, batch traceability, and a Certificate of Analysis.

Related Research Compounds

Researchers interested in the CJC-1295 & Ipamorelin & GHRP-2 Blend may also find the following related compounds relevant to their work:

• CJC-1295 (Mod GRF 1-29) — Individual GHRH analog researched for GH synthesis and pulsatile secretion.
• Ipamorelin — Individual GHRP researched for selective GH release with minimal cortisol elevation.
• GHRP-2 — Individual GHRP researched for broader GH release and hypothalamic effects.
• CJC-1295 & Ipamorelin Blend — Two-peptide GHRH/GHS blend with selective GH release.

Explore Growth Hormone Peptides

The CJC-1295 & Ipamorelin & GHRP-2 Blend belongs to the Growth Hormone Peptides category of research compounds. Growth Hormone Peptides products are studied for their potential roles in GH axis signaling, metabolic regulation, and growth-related pathways. Generally, researchers who buy this blend in Switzerland often pair it with related compounds in this category to explore complementary pathways in GH research and metabolic studies.

Explore Growth Hormone Blends

Researchers studying multi-peptide GH axis signaling and synergistic GH release may also find relevant compounds in the Growth Hormone Blends subcategory. This triple blend’s combination of GHRH and dual GHS pathways makes it a valuable tool for investigating receptor pharmacology and convergent GH signaling.

Explore Muscle & Performance

Researchers studying muscle preservation, recovery, and performance-related mechanisms may also find relevant compounds in the Muscle & Performance category. The blend’s effects on GH-dependent anabolic signaling make it a valuable tool for investigating muscle function and recovery.

Further Research

For researchers seeking to deepen their understanding of the CJC-1295 & Ipamorelin & GHRP-2 Blend and its research applications, the following areas may warrant further investigation:

• The relationship between combined GHRH/GHS activity and specific downstream signaling pathways in different cell types
• Comparative studies between the triple blend and individual components in various GH axis and metabolic models
• The potential for dual GHS-R1a agonism (Ipamorelin + GHRP-2) to produce more complete receptor activation
• Mechanistic studies on peptide stability and compatibility in blended systems
• Exploration of the blend’s effects on different tissue systems beyond musculoskeletal and metabolic models

Research Disclaimer

The CJC-1295 & Ipamorelin & GHRP-2 Blend is a research peptide formulation supplied for laboratory research use only. Researchers must not use it for human consumption, injection, or any form of therapeutic application. Moreover, this product is not a medicine, pharmaceutical, or medical device. Furthermore, Swissmedic, the FDA, EMA, or any other regulatory authority have not approved it for human use. Researchers should consult Swissmedic for applicable regulations and guidance on research peptide handling in Switzerland.

Generally, the information provided on this page is for educational and scientific reference purposes only. Therefore, it does not constitute medical advice, treatment recommendations, or dosing instructions. Ultimately, researchers bear the responsibility for ensuring that their use of this product complies with all applicable laws, regulations, and institutional guidelines.

Finally, all research involving peptide blends should be conducted by qualified personnel in appropriate laboratory settings with proper safety protocols.